Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17085440 | 0.90 | SLC6A2 (0.52) | OPRM1OPRD1OPRK1F2PLG | |
| SCHEMBL29944964 | 0.86 | OPRM1 (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29351630 | 0.84 | OPRM1 (0.58) | OPRM1OPRD1OPRK1DPP4DPP8 | |
| SCHEMBL3817152 | 0.84 | OPRM1 (0.61) | OPRM1OPRD1OPRK1F2 | |
| SCHEMBL3812839 | 0.83 | OPRM1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29710134 | 0.82 | SLC6A2 (0.59) | OPRM1OPRD1OPRK1 | |
| Acetic Acid SCHEMBL10728075 | 0.82 | F2 (0.56) | OPRM1OPRD1OPRK1F2PLG | |
| SCHEMBL30440339 | 0.82 | OPRM1 (0.56) | OPRM1OPRD1OPRK1DPP4DPP8 | |
| SCHEMBL29641544 | 0.82 | OPRM1 (0.56) | OPRM1OPRD1OPRK1DPP4DPP8 | |
| SCHEMBL16566062 | 0.82 | DPP8 (0.52) | OPRM1OPRD1OPRK1DPP8F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007120864-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE | SHIRE LLC (US) | 2007-10-25 | — | — | WO | disclosed |